Management of HIV Patients with Bacterial Pneumonia and PCP

Diagnosis and Clinical Differentiation

HIV patients with bacterial pneumonia typically present with acute onset of fever, chills, productive cough with purulent sputum, and dyspnea, with physical examination revealing focal consolidation and/or pleural effusion on lung examination 1
Bacterial pneumonia typically shows unilateral, focal, segmental, or lobar consolidation on chest radiograph, though HIV patients may present with multifocal or multilobar involvement 2
Obtain blood cultures before starting antibiotics due to increased incidence of bacteremia in HIV patients 3
Always consider tuberculosis in HIV patients with pneumonia; collect three sputum specimens for AFB smear and culture when TB is suspected 2

The Centers for Disease Control and Prevention recommends first-line treatment for PCP is TMP-SMX at a dosage of 15-20 mg/kg/day (TMP component) and 75-100 mg/kg/day (SMX component), divided into 3-4 doses for 21 days 3
Alternative regimens for patients who cannot tolerate TMP-SMX include dapsone plus trimethoprim 3
Intravenous pentamidine is an alternative regimen for patients who cannot tolerate TMP-SMX 3

For outpatient treatment of bacterial pneumonia in HIV patients, oral beta-lactam (high-dose amoxicillin, amoxicillin-clavulanate, cefpodoxime, or cefuroxime) plus oral macrolide (azithromycin or clarithromycin) is recommended 3
For non-ICU inpatient treatment, IV beta-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus a macrolide is recommended 3
Doxycycline can be used as an alternative to macrolide 3
For ICU treatment, IV beta-lactam plus either IV azithromycin or an IV respiratory fluoroquinolone is recommended 3
For patients with risk factors for Pseudomonas, piperacillin-tazobactam 4.5 g IV every 6 hours is recommended 4
Alternative treatment for patients with risk factors for Pseudomonas includes meropenem 1 g IV every 8 hours combined with either ciprofloxacin or levofloxacin 5

Never use macrolide monotherapy for bacterial pneumonia in HIV patients due to increased risk of drug-resistant Streptococcus pneumoniae 3, 4
Avoid fluoroquinolone monotherapy when tuberculosis is suspected, as it may mask TB symptoms and delay appropriate multi-drug TB therapy 4

TMP-SMX prophylaxis is recommended for HIV patients with CD4+ counts <200/μL to prevent PCP 3
Annual influenza vaccination is recommended for all HIV-infected persons 3
Pneumococcal vaccination is recommended for HIV-infected patients 3

Monitor clinical response to therapy, with expected improvement in symptoms within 48-72 hours 3
Consider alternative diagnoses, especially tuberculosis, if a patient fails to respond to appropriate therapy 3